anmelden
Analysen von Matthew Weston
| 08:01 | Bayer Buy | UBS AG | |
| 17.06.26 | Bayer Buy | UBS AG | |
| 15.06.26 | GSK Neutral | UBS AG | |
| 10.06.26 | GSK Neutral | UBS AG | |
| 09.06.26 | GSK Neutral | UBS AG | |
| 09.06.26 | Bayer Buy | UBS AG | |
| 05.06.26 | Bayer Buy | UBS AG | |
| 29.05.26 | GSK Neutral | UBS AG | |
|
Werbung
|
|||
| 28.05.26 | Bayer Buy | UBS AG | |
| 13.05.26 | Merck Buy | UBS AG | |
| 13.05.26 | Bayer Buy | UBS AG | |
| 08.05.26 | Bayer Buy | UBS AG | |
| 08.05.26 | Novo Nordisk Neutral | UBS AG | |
| 07.05.26 | Merck Buy | UBS AG | |
| 29.04.26 | Novartis Neutral | UBS AG | |
| 29.04.26 | Bayer Buy | UBS AG | |
| 28.04.26 | Novartis Neutral | UBS AG | |
| 28.04.26 | Bayer Buy | UBS AG | |
| 27.04.26 | Sanofi Neutral | UBS AG | |
| 24.04.26 | Sartorius vz. Neutral | UBS AG | |
| 24.04.26 | Roche Buy | UBS AG | |
| 24.04.26 | Sanofi Neutral | UBS AG | |
| 23.04.26 | Sartorius vz. Neutral | UBS AG | |
| 17.04.26 | Sartorius vz. Neutral | UBS AG | |
| 17.04.26 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 13.04.26 | Bayer Buy | UBS AG | |
| 10.04.26 | GSK Neutral | UBS AG | |
| 10.04.26 | AstraZeneca Buy | UBS AG | |
| 10.04.26 | Sanofi Neutral | UBS AG | |
| 10.04.26 | Novo Nordisk Neutral | UBS AG | |
| 10.04.26 | Roche Buy | UBS AG | |
| 10.04.26 | Novartis Neutral | UBS AG | |
| 30.03.26 | Sanofi Neutral | UBS AG | |
| 23.03.26 | Novartis Neutral | UBS AG | |
| 23.03.26 | Sartorius vz. Neutral | UBS AG | |
| 16.03.26 | Bayer Buy | UBS AG | |
| 13.03.26 | Sartorius vz. Neutral | UBS AG | |
| 06.03.26 | Roche Buy | UBS AG | |
| 05.03.26 | Merck Buy | UBS AG | |
| 26.02.26 | AstraZeneca Buy | UBS AG | |
| 26.02.26 | GSK Neutral | UBS AG | |
| 25.02.26 | Bayer Neutral | UBS AG | |
| 23.02.26 | Novo Nordisk Neutral | UBS AG | |
| 18.02.26 | Bayer Neutral | UBS AG | |
| 10.02.26 | AstraZeneca Buy | UBS AG | |
| 06.02.26 | Novartis Neutral | UBS AG | |
| 06.02.26 | Novo Nordisk Neutral | UBS AG | |
| 06.02.26 | Bayer Neutral | UBS AG | |
| 05.02.26 | Novo Nordisk Neutral | UBS AG | |
| 04.02.26 | Novartis Neutral | UBS AG | |